연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2023년 | 2022년 | 2021년 | 2020년 | 2019년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 173편 | 163편 | 184편 | 135편 | 144편 |
| 공동 | 120편 | 115편 | 136편 | 168편 | 167편 | |
| 합계 | 293편 | 278편 | 320편 | 303편 | 311편 | |
1461. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Han SW1, Lee HJ, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Kim TY.
Int J Cancer. 2013 May 1;132(9):2209-16. doi: 10.1002/ijc.27888. Epub 2012 Oct 29.
Link
1460. Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy.
Lee DW1, Han SW, Lee HJ, Rhee YY, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Kim TY.
Br J Cancer. 2013 May 28;108(10):1978-84. doi: 10.1038/bjc.2013.232. Epub 2013 May 7.
Link
1459. Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing.
Han SW1,?Kim HP,?Shin JY,?Jeong EG,?Lee WC,?Lee KH,?Won JK,?Kim TY,?Oh DY,?Im SA,?Bang YJ,?Jeong SY,?Park KJ,?Park JG,?Kang GH,?Seo JS,?Kim JI,?Kim TY.
PLoS One. 2013 May 21;8(5):e64271. doi: 10.1371/journal.pone.0064271. Print 2013.
Link
1458. Hypoxia reduces endothelial Ang1-induced Tie2 activity in a Tie1-dependent manner.
Yun JH1, Lee HM, Lee EH, Park JW, Cho CH.
Biochem Biophys Res Commun. 2013 Jul 12;436(4):691-7. doi: 10.1016/j.bbrc.2013.06.018. Epub 2013 Jun 14.
Link
1457. Bispecific Her2 × cotinine antibody in combination with cotinine-(histidine)2-iodine for the pre-targeting of Her2-positive breast cancer xenografts.
Yoon S, Kim YH, Kang SH, Kim SK, Lee HK, Kim H, Chung J, Kim IH.
J Cancer Res Clin Oncol. 2014 Feb;140(2):227-33. doi: 10.1007/s00432-013-1548-4. Epub 2013 Dec 1.
Link
1456. Application of bispecific antibody against antigen and hapten for immunodetection and immunopurification.
Kim H, Park S, Lee HK, Chung J.
Exp Mol Med. 2013 Sep 27;45:e43. doi: 10.1038/emm.2013.83.
Link
1455. Reporter gene imaging.
Youn H1, Chung JK.
AJR Am J Roentgenol. 2013 Aug;201(2):W206-14. doi: 10.2214/AJR.13.10555.
Link
1454. cAMP signalling decreases p300 protein levels by promoting its ubiquitin/proteasome dependent degradation via Epac and p38 MAPK in lung cancer cells.
Jeong MJ1, Kim EJ, Cho EA, Ye SK, Kang GH, Juhnn YS.
FEBS Lett. 2013 May 2;587(9):1373-8. doi: 10.1016/j.febslet.2013.03.010. Epub 2013 Mar 20.
Link
1453. Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy.
Kim JW1, Kim JH, Im SA, Lee KH, Kim JS, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA.
Cancer Chemother Pharmacol. 2013 Nov;72(5):1023-9. doi: 10.1007/s00280-013-2268-9. Epub 2013 Sep 15.
Link
1452. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW1, Kim JH, Im SA, Kim YJ, Han HS, Kim JS, Lee KH, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA.
Cancer Chemother Pharmacol. 2013 Jul;72(1):109-15. doi: 10.1007/s00280-013-2174-1. Epub 2013 May 15.
Link